Can Fite Biopharma Ltd 's

Name: Can Fite Biopharma Ltd Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

CANF Sales vs. its Competitors Q4 2025

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

<< CANF Stock Performance Comparisons

Can Fite Biopharma Ltd 's Comment on Competition and Industry Peers

The company operates in competitive markets for psoriasis therapeutics and hepatocellular carcinoma (HCC) treatments. In the psoriasis field, key competitors include Amgen, Johnson & Johnson, Pfizer, Novartis, Abbvie, Eli Lilly, Bristol-Myers Squibb, UCB, Takeda, and Alumis. In the HCC field, competitors include Bayer, Exelixis, Merck, Roche, Eisai, AstraZeneca, BeOne Oncology, Novartis, and Bristol-Myers Squibb. These competitors often possess significantly greater financial and other resources. The company recognizes that competitors may independently develop similar technologies and that patent protections may offer limited competitive advantages.

<< See the full list of CANF competitors

*Market share is calculated based on total revenue.

News about Can fite Biopharma Ltd Contracts

Strategic Capital Raise Can-Fite BioPharma Secures $3 Million Through Registered Direct Offering of American Deposita...

April 14, 2025
In a significant move to bolster its financial resources, Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a leading biotechnology entity specialising in pioneering small-molecule drugs for the treatment of oncological and inflammatory diseases, has announced the successful execution of definitive agreements pursuant to a registered direct offering. The offering, which encompasses 2,500,000 of the Company s American Depositary Shares (ADSs) at an attractive purchase price of $1.20 per ADS, is expected to yield gross proceeds of $3.0 million. The transaction is anticipated to close on or about April 15, 2025, contingent upon the usual customary closing conditions.This capital influx comes as Can-Fi...

CANF's Stock Performance relative to its Competitors

Publicly Traded Peers of Can fite Biopharma Ltd

Sources: Can fite Biopharma Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Can fite Biopharma Ltd versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.